Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes
August 27, 2024 05:02 ET
|
Amarna Therapeutics
Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes Leiden, The Netherlands, 27th August 2024 - Amarna...
Correction: Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
June 17, 2024 05:39 ET
|
Amarna Therapeutics
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1...
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
June 17, 2024 05:23 ET
|
Amarna Therapeutics
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1...
Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
April 19, 2024 04:08 ET
|
Amarna Therapeutics
Leiden, The Netherlands, 19 April 2024 – Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Type...